- Home
- Companies
- asia middle east
- inflammatory effects
Show results for
Refine by
Locations
- Asia & Middle East
- Afghanistan
- Armenia
- Azerbaijan
- Bahrain
- Bangladesh
- Bhutan
- Brunei Darussalam
- Cambodia
- China
- East Timor
- Georgia
- Guam
- India
- Indonesia
- Iran
- Iraq
- Israel
- Japan
- Jordan
- Kazakhstan
- Kuwait
- Kyrgyzstan
- Laos
- Lebanon
- Malaysia
- Maldives
- Mongolia
- Myanmar
- Nepal
- North Korea
- Oman
- Pakistan
- Palestinian Territories
- Philippines
- Qatar
- Russia
- Saudi Arabia
- Singapore
- South Korea
- Sri Lanka
- Syria
- Taiwan
- Tajikistan
- Thailand
- Turkmenistan
- United Arab Emirates
- Uzbekistan
- Vietnam
- Yemen
Inflammatory Effects Suppliers In Asia Middle East
4 companies found
based inYongin, SOUTH KOREA
Bilix is established based on the world’s first PEGylated bilirubin platform technology to produce numerous “First in Class” in anti-inflammatory and “Best in Class” in cancer therapy drugs in addition to achieving other business platform such as ...
Many inflammatory diseases are associated with reactive oxygen species(ROS) in the body. The bilirubin nanoparticle has strong antioxidant, ROS scavenging, and immune modulating properties which effectively ...
based inKfar-Saba, ISRAEL
Medical Quant company is a medical device company focused on innovative science-based products devices for home self health care and clinical professional use. We strive to bring relief to more and more people around the world, by providing the best ...
based inDallas, TEXAS (USA)
Santa Cruz Biotechnology is a world leader in the development of products for the biomedical research market. Over the past thirty years, Santa Cruz Biotechnology has focused on the ongoing development of research monoclonal antibodies, ...
Mead Acid is an omega-9 fatty acid and anti-inflammatory precursor in the biosynthesis of prostaglandins, thromboxanes and ...
based inMelbourne, AUSTRALIA
Mesoblast is using its proprietary mesenchymal lineage cell technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex inflammatory diseases resistant to conventional standard of care. ...
MPC-06-ID is a Phase 3 product candidate for the treatment of chronic low back pain caused by disc degeneration (CLBP). It is being developed for patients who have exhausted conservative treatment options, may have failed epidural steroid ...